Annual Financial Report Fiscal Year 2015–16

(June 1, 2015–May 31, 2016)

MAPS Bulletin Winter 2016: Vol. 26, No. 3 – Annual Report

Download this article.

Each year, the Multidisciplinary Association of Psychedelic Studies (MAPS), a 501(c)(3) non-profit organization, presents its year-end consolidated financial report with substantial details about where our income comes from and how our expenses are allocated and prioritized. We do this as a commitment to transparency and an invitation for dialogue. This report describes our most recently completed Fiscal Year from June 1, 2015 to May 31, 2016 (FY16) and consolidates financial information from MAPS, MAPS Inc. (MAPS’ Canadian research operation) and the MAPS Public Benefit Corporation (MPBC), a subsidiary that is 100% owned by MAPS. The MAPS Board of Directors created the MPBC in FY15 to conduct MAPS’ clinical research and eventually to market MDMA as a prescription medicine. Additional information on MPBC can be found at and in a MAPS bulletin article, “Introducing the MAPS Public Benefit Corporation” (Vol.25, #1, p. 4–5).

MAPS’ FY16 Annual Report demonstrates our efforts to strategically leverage the resources that MAPS supporters have so generously empowered the staff to use to transform psychedelics and marijuana into FDA-approved prescription medicines. Medicalization of psychedelics and marijuana is an essential part of our larger mission to mainstream these substances into our culture for a wide range of beneficial uses.

MAPS’ annual financial reports, audits, and IRS 990 forms can be found at If you have any questions or comments about anything in this financial report, or would like to become more involved, we invite you to contact We also invite you to donate to MAPS to expedite legal access for many millions of people in the US and around the world to the healing and spiritual potentials of psychedelics and marijuana.


MAPS’ net revenue in Fiscal Year 2016 (June 1, 2015–May 31, 2016) totaled $5,186,379 from more than 2,500 donors, events, sales, and investments, with $4,687,600 in contributed revenue. Net revenue in FY16 was more than $2 million above the $3,055,686 that MAPS raised in the previous year. Expenses totaled $4,442,419, more than $1.1 million over the previous year’s expenses of $3,256,007 as MAPS expands in preparation for Phase 3 MDMA/PTSD research. In FY16, MAPS increased its net assets by $743,960 to $9,906,814, still less than half of what we anticipate needing to spend on Phase 3 MDMA/PTSD research.

For historical information on overall annual income, expenses and net assets, see Chart 1. Charts 2 and 3 present detailed information on FY16, with Chart 4 projecting annual income, expenses and net assets for FY17. Chart 5 presents data on which of MAPS’ assets are restricted to which specific projects and estimates these numbers for FY17. Chart 6 is a detailed discussion of MAPS’ projected and actual expenses for FY16 on a project by project basis, with estimates for FY17. Charts 7–10 are about MAPS’ MDMA Phase 2 and Phase 3 research expenses through FY21. Chart 11 reviews our marijuana/PTSD research cost projections.

Revenue Review for Fiscal Year 2015-16

The increase in revenue in FY16 can largely be attributed to two new generous donors giving $1 million and $1.5 million. Moshe Tov Kreps pledged $1 million, mostly for MAPS’ research into MDMA-assisted psychotherapy for PTSD in Israel. The Tides Foundation pledged $500,000 a year for three years for operational expenses for a total of $1.5 million, with accounting rules requiring booking multi-year grants all in the first year rather than over the years during which the funds will actually be received. A total of $1.65 million of FY16 net revenue of $5,186,379 was in multi-year grants that will be received in future years.

Major support totaling $1,104,080 was received for MAPS’ Phase 3 MDMA-assisted psychotherapy studies; this includes $500,000 for Phase 3 Israeli MDMA/PTSD research, $301,080 for ongoing Phase 3 Therapist Training in which over 60 therapists have already been trained to conduct MDMA-assisted psychotherapy, $150,000 for Phase 3 General Support which has been used to design the Phase 3 protocol and prepare submissions to FDA reporting on our Phase 2 data, select sites, and recruit staff, and $153,000 towards the purchase of a kilogram of GMP MDMA ($400,000 required) for Phase 3 research raised by MAPS and its partner MAPS Canada.

Additional support in the amount of $914,036 was donated for a range of projects. These projects include: $881,003 for the completion of Phase 2 MDMA-assisted psychotherapy projects, $24,249 to support MAPS’ obtaining approval for our study of marijuana for treating PTSD in 76 US veterans (with the approved study itself funded by a $2.15M cost reimbursable grant from the CO Dept. of Public Health and Environment the income of which will be recognized monthly as received over the next three years), $5,000 for future work on the impact of Marijuana on opioid addiction, $2,454 for Ibogaine funding to complete reports on observational studies in New Zealand and Mexico, and $1,300 for Ayahuasca/PTSD research. In total, $1,993,699 was raised for MDMA-related research and $33,003 was raised for Marijuana related and other projects for a total of $2,018,116.

MAPS also raised an additional $503,084 for its educational initiatives. These include $124,435 for psychedelic harm reduction, $18,828 for conference and events, and $359,821 in Fiscal Sponsorships (see Chart 6, Note 1).

The balance of MAPS’ funds raised in FY16, in the amount of $2,732,600, was designated for unrestricted use. Of this amount, $1.5 million is from the Tides Foundation grant of $500,000 a year for three years for operational expenses.

Due to fluctuations in the stock market, MAPS’ FY16 net revenue was negatively impacted by $240,637 in unrealized losses in our portfolio at the San Francisco Foundation as of May 31, 2016. As of the date of the writing of this report almost five months into FY17, these losses have been recovered.

Sources of Revenue in Fiscal Year 2015-16

Following this report is a list of MAPS donors of $120 or more, who along with an additional 1,926 individuals and 11 organizations who donated up to $120, make our work possible. MAPS staff are profoundly grateful for our donors who empower us with resources and also their hopes and trust.

About 90% of net revenue was contributed by 2,547 individual donors and family foundations. In FY16, MAPS saw an 246% increase in the amount of major donations ($20,000+) and a 10% increase in mid-level donations ($1,000–$19,999), with the total number of donors at these levels also increasing from the previous fiscal year. However, grassroots donations (under $1,000) stayed about the same and the total number of grassroots donors decreased. In FY15, the Legalizing Psychedelic Therapy crowdfunding campaign brought in 1,000 donors alone. There was no campaign of this scale in FY16 which explains the decrease in number of grassroots donors in FY16 from the previous year. Overall, the number of donors decreased only slightly in FY16 by about 140, with a renewal rate of 27%. The low renewal rate can be attributed to MAPS crowdfunding campaigns which generally engage large numbers of first-time donors most of whom we have not been able to persuade to renew their support.

Grants revenue of $3.345 million was received from family foundations and donor advised funds. In all cases, we have a pre-existing relationship with the courageous and visionary donors. We a
nticipate eventually obtaining funding from large, more staff-driven, perpetual foundations once we’ve completed negotiations with FDA regarding the design of our Phase 3 MDMA/PTSD studies and can present complete budgets to these foundations which reflect the FDA-approved design of these studies.

In FY16 we celebrated our 30th Anniversary with a banquet and celebration in Oakland, CA. In conjunction with our 30th Anniversary, we launched our Global Psychedelic Dinners, a peer-to-peer campaign raising funds for our purchase of 1 kilogram of GMP MDMA. Over 82 MAPS supporters hosted fundraising dinners in 16 countries which raised over $45,059. A total of $153,000 was raised for GMP MDMA through the efforts of the 30th Anniversary and the Global Psychedelic Dinners. Those who wish to host a Global Psychedelic Dinner still have a chance to do so by visiting

MAPS’ long-term account for our assets, The Curing Fund, is managed by the San Francisco Foundation and is invested in the stock market. The Curing Fund began FY16 with a balance of $6,714,261 and experienced a loss of $243,334 (3.6%) as of May 31, 2016. This represents a substantial improvement from the estimated loss of $615,316 reported in February 2016. There were no new contributions made to the fund in FY16 as all major receipts had been used to support operating expenses. About $6.05 million of the Curing Fund funds have been board-restricted to Phase 3 MDMA/PTSD research.

Our fiscal sponsorship program had gross revenue of $359,821, an average 5% administrative fee charged, and the balance disbursed to projects that are in alignment with MAPS’ vision and mission.

Product sales and event registrations combined are each less than 5% of our revenue, but remain important aspects of our work as the income offsets the costs of events and products, which serve to draw new supporters, strengthen our relationships to current supporters, and promote our message.

Expense Review for Fiscal Year 2015-16

In Fiscal Year 2016, program costs totaled 85.9% of all expenses. Programs include Research expenses of $2,161,926 (48.7%), Education and Communication expenses of $1,653,548 which includes Harm Reduction of $287,397 and Fiscal Sponsorships of $351,889 (37.2%). Fundraising expenses were $349,390 (7.8%) and Administrative expenses were $277,555 (6.3%).

Our primary expenditure in FY16 was research into MDMA-assisted psychotherapy with expenses of slightly more than $2 million. MAPS spent $1,099,431 on completing Phase 2 research into MDMA-assisted psychotherapy for the treatment of PTSD and associated projects and $609,334 was spent in preparation for Phase 3 MDMA/PTSD research. We also continued our study looking at the safety and efficacy of using MDMA-assisted therapy for anxiety in adults on the autism spectrum ($106,310), and continued our study of MDMA-assisted psychotherapy for end-of-life anxiety ($197,978). Both studies are expected to be completed by the end of FY17. An additional ($12,783) was spent on the MDMA/PTSD Memory Reconsolidation mechanism of action study.

In FY16 we completed gathering primary outcome data from all subjects in our international series of Phase 2 MDMA/PTSD pilot studies and have gathered almost all of the 12-month follow-up data. In addition to our core MDMA/PTSD drug development research, we continued to prepare, fund and sponsor a series of studies in collaboration with researchers who work with the U.S. Department of Veterans Affairs’ National Center for PTSD using MDMA combined with more traditional methods for treating PTSD including Cognitive-Behavioral Conjoint Therapy (CBCT) and Prolonged Exposure (PE). We received FDA and DEA approval for our Charleston CBCT study treating couples/dyads, where one member of the couple/dyad has PTSD and the other member is impacted. In FY16 MAPS spent $37,275 on these collaborative projects. These studies are possible thanks to the work of Dr. Richard Rockefeller who devoted his time and strategic wisdom in deepening MAPS’ relationship with the Department of Defense and Department of Veterans Affairs (VA).

Marijuana research expenses totaled $129,714. Nearly all of this covered the costs to develop and obtain approval of the protocol, and set up study sites, for a pilot study in which marijuana will be tested to manage PTSD symptoms in 76 veterans with treatment-resistant PTSD. Half of the subjects will be treated at Johns Hopkins University and half will be treated in Phoenix, Arizona. In FY16 we received all regulatory approvals needed to begin the study, including FDA, DEA, Public Health Services (PHS), National Institute on Drug Abuse (NIDA), Johns Hopkins IRB, University of Pennsylvania IRB, and the Copernicus IRB. MAPS funds spent on regulatory approval were not reimbursable by our contract with the Colorado Department of Public Health which only became active after all of the approvals had been obtained. MAPS currently has about $80,000 in non-reimbursable expenses for our marijuana/PTSD study. We’ve thus leveraged about $80,000 of MAPS expenses into a $2.15 million grant.

Education expenses of $1,653,548 include events, publications, communications, psychedelic harm reduction, and fiscal sponsorships. Conferences, events, and initiatives had expenses of $491,653. The event with the largest expense was our 30th Anniversary Banquet and Celebration which cost $96,548 and raised more than $153,000 towards the purchase of MDMA for Phase III research. In FY16 MAPS produced nine events and provided sponsorship, speakers, tables, formal representatives, and/or promotional support for 35 outreach events. Expenses on general advocacy were $73,892, Americans for Safe Access (ASA) Medical Marijuana Education and outreach expenses were $107,074, and the successful work to end the NIDA Monopoly incurred expenses of $11,150.

Communications expenses of $522,610 include active engagement in public education through media contacts, website and social media presence, publishing three MAPS Bulletins, 12 Email Newsletters and several books. We maintained,,,,,, and MAPS experienced a 30% to 100% increase in exposure compared to the previous year in all our social media outlets (Facebook, Twitter, YouTube, Google+, LinkedIn, Pinterest, Tumblr, Instagram, and reddit). MAPS also received 394 unique media mentions from online and print publications. Media outlets include: New York Times, NPR, Salon, U.S. News, San Francisco Chronicle, The Washington Post, NBC Bay Area, Popular Science, Aljazeera, The Wall Street Journal, Business Insider, Fox 10, VICE, Rolling Stone, The Huffington Post, The New Yorker, Los Angeles Times,, Military Times, CBS News, Marie Claire, and many more.

Our Zendo Project psychedelic harm reduction program incurred costs of $287,000 with the largest expense of $84,778 being the building of a new cardboard Zendo structure to be used at Burning Man, 91% of which was funded by grants of $77,000. The Zendo Project provided services at 6 major festivals including: Burning Man (Black Rock City, NV), Envision (Costa Rica), AfrikaBurn (South Africa), Lightning in a Bottle (Bradley, CA), Symbiosis (Oakdale, CA), Youtopia (San Diego); and other events such as Bicycle Day (San Francisco, CA), The Denver Cannabis Cup, and more. The Zendo Project also provided on-site harm reduction consultation services to the Electric Daisy Festival in Las Vegas, NV. Over the past two years (2015 to 2016), the Zendo Project has served over 1,516 people, and trained over 666 new volunteers. The Zendo project now has three structures in which to provide a safe and supportive environment at festivals. We’re building awareness and support for the provision of psychedelic harm reduction services through event promoters at events and venues in the US and around the world. At the most recent Burning
Man, in MAPS FY17, for the first time ever, the Burning Man organization (BMorg) included an insert about Zendo in the greeter package given to over 70,000 attendees, and permitted us to state that Zendo provides “psychedelic harm reduction”, rather than the language we’d been required to use in previous years of “psychological support services”. As a result of this greater visibility, Zendo served over 470 guests, three times more than in any previous year. Most astoundingly, the BMorg arranged for Sara Gael, Director of MAPS’ Zendo Project, to speak about Zendo to about 60 federal police from the Bureau of Land Management (BLM), who ended up sympathetically supporting Zendo and psychedelic harm reduction at Burning Man.

MAPS continued its long-running Fiscal Sponsorship program in FY16 with donations totaling $359,821. This program supports projects that are in alignment with MAPS’ mission and vision by offering donors a way to provide support for projects conducted by non-501(c)(3) organizations by passing funds through a 501(c)(3) nonprofit sponsor organization. MAPS monitors the project budget, takes a small fee, and sends the donor a receipt for their contribution.

Major contributions include donations of $200,161 for the Ayahuasca Foundation’s research facility in Peru, $45,100 for the International Center for Ethnobotanical Education, Research & Service (ICEERS) which works towards the integration of iboga, Ayahuasca, and other traditional plants into Western society, $87,753 for the films From Shock to Awe ($43,101), Huxley’s Exit ($30,213), Divinorum ($10,695), the multimedia project “Sublime Visions” ($3,744) dedicated to the therapists and visionaries working with psychedelics as contemporary therapeutic medicines, and donations of $20,231 for several other educational projects including the Bluelight Forum on psychedelic drugs ($13,170), Women’s Alliance for Medical Marijuana (WAMM) and its educational work in the compassionate use of medical marijuana ($4,200), Global Ibogaine Therapy Alliance (GITA) and its work supporting the sacramental use of Iboga ($8,165), and Cosmic Sister and its work educating the public on the unique psychedelic experiences of women ($1,059).

Fundraising expenses were $349,390. Of that amount, $255,719 are primarily for staff, mail and delivery, donor research and database costs, with another $60,516 for campaigns including premiums for crowd funding and other efforts, and fundraising events and travel and lodging for individual donor visits. Fundraising accounts for 7.8% of MAPS’ expenses.

Operational costs were $277,555. There are the unglamorous but necessary expenses of staffing, office rent, taxes, fees, accounting, information technology, equipment, supplies, and postage. Operations accounts for 6.3% of MAPS expenses.

Projections Fiscal Year 2016-17

As an overview, in FY17 we plan on shifting our focus to multi-site Phase 3 studies required for FDA approval of prescription use of MDMA-assisted psychotherapy for PTSD. Based on our current timeline, we anticipate submitting our New Drug Application (NDA) to the FDA in 2021. In FY17, we’re projecting total research expenses of $3.9 million (63.9%) and about $1.57 million for our communications and public education programs including the Zendo Project and fiscal sponsorship (25.8%), with $632,529 for fundraising and administration (10.3%).

Estimated spending ($6.10M) in FY17 is projected to be almost $2M more than in FY16. Of this amount, programmatic expenses—research ($3.9m) and education ($1.57m)—will account for 89.6% of total expenses. The increase primarily reflects the increased tempo of MAPS’ anticipated early 2017 approval for its Phase III MDMA/PTSD research on which we’ll spend about $2.1 million in FY17. There will be $602,828 in expenses for related Phase 2 MDMA/PTSD projects, which includes completion of follow-ups, publishing results, and several secondary studies conducted with researchers affiliated with the Veterans Administration including the study of MDMA combined with Cognitive-Behavioral Conjoint Therapy (CBCT) and MDMA combined with Prolonged Exposure. Additional expenditures of $296,283 are projected on other MDMA research projects include MDMA-assisted psychotherapy in people suffering from anxiety as a result of life-threatening illness ($188,736), and MDMA-assisted psychotherapy in autistic adults with social anxiety ($70,210). Phase II marijuana research ($1,010,275) is almost entirely dedicated to MAPS’ investigation into the impact of marijuana on the symptoms of PTSD in 76 US veterans ($1,008,125) with the balance of $2,150 for general marijuana-related expenses. The balance of research expenditures of $6,720 is split amongst MAPS projects on Ayahuasca, Ibogaine, and LSD.

In addition, MAPS Psychedelic Science 2017 conference is expected to cost an additional $569,000 during FY17 (with income anticipated of $625,000). MAPS will be co-hosting our Psychedelic Science 2017 conference in Oakland, California with the Beckley Foundation. PS2017 is a six-day global gathering, featuring three days of conference presentations and three days of workshops, a Sunset Cruise on the San Francisco Bay, the world’s first Psychedelic Comedy Banquet, and more. This is a space for the scientific and psychedelic community to share and discover new research into the benefits and risks of MDMA, LSD, psilocybin, ayahuasca, ketamine, ibogaine, medical marijuana, and more. For more info, visit

We currently project income of $3.37 million from anticipated donors in FY17, about $369,500 less than in FY16. In FY16 we received a large number of new major donations and pledges, over $3 million of which were not initially anticipated. In FY17 we hope to obtain new major contributors but have not included any such donations in our FY17 income projections since these new relationships are still in the process of coming to fruition. Additional funding from the State of Colorado medical marijuana research grant ($1.08M), conference income ($625,000), sales income ($115,000), fiscal sponsorship income ($100,000), and harm reduction income ($28,000) will leave MAPS with a $920,554 deficit between projected income and expenses. This deficit will either be funded from additional donations from existing or new donors, or will be drawn down from MAPS’ net assets, potentially leaving MAPS with $8.98 million at the end of FY17, still less than half of what we anticipate needing for Phase 3 MDMA/PTSD expenses.


FY16 was a remarkably successful year. Expenses were about $1.2 million more than in any previous year in MAPS’ 30-year history yet we still managed to inspire enough donations and multi-year pledges to end the year with a surplus of $743,960. Expenses in FY17 are projected to be about $1.6 million more than in FY16, with a deficit projected to be $920,554. Our challenge for FY17 is to raise sufficient amounts of new, unanticipated donations to more than breakeven, as we expand into Phase 3 MDMA/PTSD research which we are currently estimating will cost $25 million (see Chart 8).

As I write this annual report, I’m looking forward to our FDA End of Phase 2 meeting on November 29, 2016. As you read this annual report, it’s likely to be after that meeting. I feel confident that if that meeting goes well and we are indeed on track to start Phase 3 research, that we will be able to motivate and inspire the new donors that will enable us to expand our research. The need is great for new treatments for PTSD, and our Phase 2 data on safety and efficacy is promising, especially considering that we have been enrolling chronic, treatment-resistant subjects who are the people most difficult to treat. As MAPS moves into its 31th year, , we present this financial report for your review, along with an appeal to existing MAPS donors for continued and expanded support and to new donors who are inspired to join w
ith us in our mission of healing, spirituality, and cultural evolution.

If you have any questions or comments about anything in this financial report, or would like to become more involved, we invite you to contact

MAPS Fiscal Year 2015–2016 Donors

These pledges and donations were made between June 1, 2015 and May 31, 2016. Our gratitude goes to all those who contributed to make this work possible. We share this list in part to show that a community has gathered together make a difference.

$1,000,000 & above

Tides Foundation $1,500,000
Moshe Tov Kreps $1,000,000


Riverstyx Foundation $332,000
Dr. Bronner’s $220,308
Scorpio Rising $200,000
Libra Foundation $200,000
Rockefeller Philanthropy Advisors $200,000
David Rockefeller $100,000



Adam Wiggins $60,000
Mental Insight Foundation $60,000
Jeremy Tarcher Bequest $50,000
Tim Butcher Bequest $50,000



Arjun Banker $10,000
Robert J. Barnhart $24,385
Ian Brown $11,000
Steve Chapman $18,000
Adam Denmark Cohen $10,000
Khaliya and Thomas Ermacora $10,000
John Gilmore $30,000
George Goldsmith & Katya Malievskaia $25,000
HeadCount $38,979.43
Philip Jensen $10,000
Jewish Community Foundation of LA $10,000
Bill Linton $10,000
Laura and Ed Littlefield $40,000
Mai Family Foundation $25,000
William N. Melton $10,000
Roger & Margot Milliken $10,000
Justin Rosenstein $10,000
René and Susan Ruiz $10,000
Britt Selvitelle $10,000
Smart Family Foundation $20,000
Robin Toor $12,005
Roland Wiederaenders $10,000
William H. Donner Foundation $15,000
Anonymous $40,000
Anonymous $10,000
Anonymous $10,000



Jeya Aerenson $1,000
AmazonSmile Foundation $2,543.65
Joakim Arfvidsson $5,000
Allan Badiner $1,000
John Balquist $1,400
Neil & Elena Boyer $1,124
Brian Brown $1,250
John Buchanan $3,500
Ulrich Buddemeier $1,000
Sheila Burgel $2,500
Frederick Burks $1,275
California Institute of Integral Studies $3,000
Giancarlo Canavisio $2,000
Elizabeth Davis $1,000
Maria O. Dines $2,000
Candra Docherty $4,500
Charles T Dunn $1,200
Paul Eastham $3,000
Dean Edell $1,958.25
Bob Eisenberg $1,000
Evolver $1,580
Leander Fortmann $1,100
Mack Fuhrer $2,000
Robert & Margaret Gansser $1,000
Nicholas Greco $1,072
Kyle Gilbertson $1,070
Bailey Gimbel $5,000
James Ginther $1,000
Michelle & Ian Glass $1,000
Peter Glynn $1,200
Jerry Greenfield $1,000
Jeffrey Guss $5,000
Gale Hayman $5,000
John Heilemann $2,500
Kevin Herbert $2,650
Highfield Foundation $2,500
Connor Hill $1,189
Peggy Hitchcock $1,000
Julie Holland $3,545
Sam Hummel, Jr. $2,000
Joshua Mailman Foundation, Inc. $5,000
David W. Kaiser $1,000
Carolyn Mary Kleefeld $5,000
Paul Kuhn, Jr. $1,000
Jeffrey Kwatinetz $5,000
Ninni Ladjevardi $1,000
Rebecca Lambert $5,000
Paige Lassen $1,000
Josh Lee $1,000
Christopher Lindstrom $1,000
Gary Lippman $5,000
Ingrid & Anthony Lombardino $1,000
Jared Luxenberg $3,000
Donald Mack $2,000
Leigh Marz & Michael Ziegler $1,000
Magaly Mauer $2,000
Chris McKulka $1,125
Daniel McMurtrie $1,000
Constance & H. Roemer McPhee $2,000
Jeff Mease $1,000
Scott Meyer $1,035
John Christoper McCormick $2,500
Stephen Milstein $1,500
Michael Montagne $1,000
Dan Mottsman $3,300
Nathan Cummings Foundation $5,000
Erin O’Keefe $3,531.55
Phil Olson $1,800
Jacob Perkins $1,585
Clifford Perlman $1,000
Patricia Phillips $2,800
Psymposia $1,175
Jessie Anne Rees $3,169.30
Caleb Reese $3,800
Jessica Reisman $2,500
Rupert Runewitsch $1,500
Ben Sessa $1,453.73
Kathleen M Shubin $5,000
Michael & Anita Siegal Family Foundation $4,000
Hilary Silver $7,750
Silver Spring Networks $1,000
Elizabeth Skelsey $1,325
Mark Smith $1,000
Anne St. Goar $3,247.58
Tahoe Wellness Cooperative $6,453.18
Max & Elena Talan $5,040
The Prentice Foundation, Inc. $3,500
Threyda $1,000
Lamara & Timothy Tillman $1,400
Carey & Claudia Turnbull $6,000
Terry Turner $1,840
David Tuttleman $5,000
Devera & Michael Witkin $7,750
Philip Wolfson $2,500
C. Dusty Yao $1,000
Matthew Zimmerman $1,000
Anonymous $1,000
Anonymous $1,000
Anonymous $1,000
Anonymous $1,000
Anonymous $1,000
Anonymous $1,000
Anonymous $1,500
Anonymous $1,500
Anonymous $2,100
Anonymous $3,000
Anonymous $5,000



Joe Bamberg
Kevin Egelston
Walker Pitman



Michael ‘tsas-Rolfes
Anthony David Adams
Ruzsa Balçzs
Henry and Sue Bass
Tom Bassett
John Bernstein
Derek Calder
Paul Caloia
Neal Castleman
Jeffrey Coleman
Jeh Cranfill
Richard Cummings
Eric & Jubilee Daniels
Troy Dayton
Carla Detchon
Anita Durst
John Dwork
Conal Elliott
Jamy Faust
James Ferrari
Leo Figgs
Darren Fortunato
Dan Girellini
George Greer & Requa Tolber
Martin Guyot
Jonathan Izak
Marty Jakle
Joel T. Kirkpatrick
Ivan & Ann Kruglak
Joel Kubby & Laura Parks
Tom Lehrer
Alex Lewin
Carla Lilley
Greg Logan
Alexander Lustberg
Katherine MacLean
Niels Maderlechner
Robert Cezar Matei
Shane Mitchell
Jon Mitchell
Annie Mithoefer
Ana-Alicia Montano
Laura Mosbacker
Daniel Nascimbeni
Matthew Neal
Benjamin O’Connor
Lawrence Ostrovsky
Christopher Pappas
Joseph & Nancy Pearl
Silvia Polivoy
Tracy Putnam
Susan P. Robbins
Doug Robinson
Steven Rooke
Marsha Ruth Rosenbaum
Justin Routt
Rebecca Sharzer
Jessie Shaw
June & Richard Shibley
Natalie Slect
Toni Starr
Dan Steinberg
Christopher Stolt
Barbara Strauss
Anja Thomas
Larry L. Wendell
James Youngblood
Daniel Zuhlke



John Adair
Kwasi Adusei
Neil Ayer
Jessica Babyak
Mark Badgley
Erik Beerepoot
Pedro Belo
James Drew A. Bennie
Michael Bissell
Matthew Blau
David Blistein
Leoni Boberg
Ashley Booth
Graham Boyd
Simon Brandt
Jeffrey Breau
Benjamin Broder
Matt Brown
Bonnie Brunet & Martin Rist
Ben Byer
James S. Campbell
John Carlock
Colin Cayer
Akira Chan
Diana Chapman
Thomas Martin Christensen
Shawna Willow Cleverdon
Mark Crosby
Sasha Cuff
Shawn Cureton
Paul Daley
Drew Daniels
Alan Kooi Davis
Andrew Dekkinga
Luca Dellamore
Derek Denuzze
Joel DeSomber
Craig Dobbin
Chris Curran Dombrowski
Daniel Drake
Darius Jaeger Farraye
William Fell
Jody Fitt
Mary Catherine Ford
Dietrich Franke
Bill Freimuth
FSU Veterans Association
Steve Gehrman
Roland & Elizabeth Gibson
Patsy An Grace
Vincent Graham
Mark Grey
Elizabeth Guaranaccia
Ray Hale
Judith Haran
Rusti T. Hauge
Craig Heacock
Alexander Heck
Dona Hill
Kevin Hoeltschi
Koen Hugelier
Andrew Jarmon
Mark Jenne
Bruce Johnson
Elsimaria Kalliosalo
Brian Kehew
Thomas Kellerhoff
Robert James Kenney II
Elliot Kharkats
Lars King
John Klaboe
Blaine K
Elise & Gerald Lazar
Star L. Le
Lawrence Leeman
Steve Lefevre
David Lenderts
Milos Levcik
Peter Lyon
Crystal & Keith MacAllum
Benjamin Malcolm
Margarita Maltseva
Ryan Markwardt
Nathan Marrs
John McIlwain
Thomas Meade
Carolyn Memmott
Mark Metzker
Jamie Mills
Eshara Mondal
Michael Mooney
Joshua Daniel Mora
David More
Nori Muster
Sarita Nori
James D. Northrup
Beth Odonnell
Peter Oehen
Kevin Parker
Nancy Bayer Perman
David Presti
John Puckett
Michael Randolph
Maggie Rauen
Carl Resnikoff
Richard Robertson
Marilyn Robie & Arthur Shechet
Brit Robinson
Nicolas Ronco
Elizabeth Roseman
Lee Rosenblatt
Giorgio Rossi
Aaron Samsonoff
Hernan Sanguinetti
Joe Saponare
Patricia Shaw Savant
Mark Schneider
Peter Schroeder
Aaron M. Segura
Ciara Sherlock
Joakim Skimutis
Andrew Skinner
Aaron Sokol
Jeff Sparks
Amanda Beth Spielman
Ashley Spivak
Pamela Stockton
Ryan Strong
Brendan Tanner
Robert G. Teeter
John Michael Thomas
Patricia B. Tomer
David Ethan Trooskin-Zoller
Taco Van Ieperen
Lauren Vazquez
Fabienne Vukotic
Dan Whipple
Joseph White
Ashley & Chuck Wile
Michael Williams
Matthias Witty
Levi Woodard
Paul Thomas Woods
James Yarnold
Alexandr Zubov



Alan Aaron
Daisy Abraham
Advanced Cannabis Solutions Corp
John Albertson
Robb Allan
Sherri Anderson
Thomas Aquino
Denny Ashkenazi
Craig Baggley
Alice Bain
Dave Henry Balkema
Keith Barry
Kurt Bartelmehs
Grant W. Baxter
Leonard Bearne
Brandon Beatty
Spencer Bednar
John W. Blyth
Cornelis Bouman
Andrew Boyd
Patrice Boyle
Timothy Bracciante
Peter M. Bradlee
Tammy Brazil-Lucas
Paul Brickey
Shaunus Brousek
Kelly Brown
Kobie Brown
Alessandro Bruni
Margaret L. Bryant
Thomas Bryce
Timothy J. Buckley
Bruce Busby
Justin Bush
Alexandre Cagli
Padma Catell
Caleb Chepesiuk
Rachel C. Chepesiuk
Charles Lee Coates
Keith Randall Coleman
Stephen Conrad
Ines Cremer
Ruth Crocker
James Crocker
Jason Crozier
Jeremy Dalnes
Brad Davis
Alan Davis
Yves De Leeneer
Diane De Marco
Valentina deCruz-Dixon
Alex Dent
Norman Don
Lee Dresang & Kari Bloedel
Nicholas Druhn
Donald Dulchinos
Douglas EkstrÜm-Ahlby
Barry Elkin
Kesha Engel
David Evans
James & Dorothy Fadiman
Danna Fason
Jacob Ferguison
Full Spectrum Recovery & Counseling
Katalin Galasi
Paul Garza
Arash Ghaffari
David E. Ginsburg
Dan Glick
Erick Godsey
Marvin & Janice Gold
Callum Golding
James Gorman
Kayla Grant
Loring Greene
Shawn Grona
Chloe Elizabeth Groom
John Gunn
Robert Gunn
Abie Hadjitarkhani
Larry and Margaret Hale
Kristine Hall
James Hammans
Charles Hayes
Andrew Hayward
Christopher Hebbe
Gary Heine
Emily Heller
Laine Herron
Regina Hess
Christopher James Hewitt
Jono Hill
Ben Holden
Lucy Hosking
Matthew Hudson
Adam Hurter
Mark Hurwit
Istvan Huszar
Michelle Indianer
Nicole Ivey
Moshe Jacobson
Ilsa Jerome
Stefanie Jones
Jenna Kachmarik
John Kaczmarzyk
Isadora Karcher
Laura S. Karst
Ryan J. Keating
Robert J. Kenney
Tom Kenny
Ryan & Allison Kiesel
Betty King
Herbert Kleber
Lawrence Klein
Steven & Kristine Klein
Barry Klein
Adam Kokelj
Jeffery Alan Kraus
Dean LaCoe
Bill and Lisa Lahey
Ricki Lake
Andrea Langlois
Alison Laytham
Mathias Lebert
Cyrena Lee
Marc Levine
Doron Levitan
Arlene Lindberg
Niklas Lindgren
John Farrell Lines
Carl Loccisano
Wiley P. Long
Audun Lovdahl
Marta Lynch
Randy Mack
Todd Malkoff
Rob Manning
Daniel Mantuani
Nick Marchese
Britany Marin
Ossi Markkula
Marissa Marquez
Elliot Marseille
Cruz Martinez
Chris Mays
Timothy McAllister
Peter McCluskey
James W. McCormick
Friederike Meckel Fischer
Bill Mehleisen
Mara Merritt
Zevic Mishor
David Moss
Joseph Motta
Mike Murphy
Roxxann Murphy
Ron Nadeau
Ethan Nadelmann & Marsha Rosenbaum
Claudio Naranjo
Tara Lynn Nelson
Anh-Kim Nguyen
Ben Nguyen-Tang-Le
Kristiina Nikkola
Jay Nitikman
David Noble
Jozo Novak
Clare O’Neill
Adrian Oberg
Runar Olsen
Kelsey Lauren Onstenk
Pacific Gas & Electric Company
Nelson B. Parmerter
James Parsons
Rick Parsons
John F. Pauly
William Pearson
Edward Pelger
John Perkins
James Pettigrew
Stephen J. Pittelli
Veronique Pittman
John Pollack & Karen Berry
Kenneth Porter
Ashley Powell
Ralph Reda
Randy Reed
Robin C. Reinach
Paul Renn
Laura Riccardo
Tom & Alexa Robbins
Ronnie D. Robertson
Martin Rohm
Richard Roth
Jeannette Rothweiler
Ben Rubin
James Rucker
Pavi Sandhu
Dominique Christine Schelble
Martin Schiffert
William Schlamp
Tim Schmidt
Don Scott
Michael Seymour
Michael Shafer
Kevin Sheehan
Chris Shelley
Stephen Eric Sienknecht
Karla Smith
Michele Soleimani
Schuyler Sowa
Ben St. Pierre
Tim Stacey
Martha Stampfer
Alexander Steeves-Fuentes
Robert Stek
Glenn E. Stoltz
Erik Storlie
Devon Stubbs
Bowen Summerton
Harry Sumnall
Blake M. Sutton
Kayla Tawoda
Eric Taylor
David Taylor
Adam Teninbaum
Shirley Tessler
Holly Thomas
John P. Thornton
Mark Thornton
Michael Tiefenthaler
Justin Todd
Taylor Trott
Eric Tsen
Katherine Turner
Karen Turner
Jade Nicole Ullmann
Jit Vaitha
Lars Van Den Broek
Sean Van Tongeren
Theo Vermont
Winifred Veronda
Henry Vistbacka
Sarah Voruz
Beth Wadman
Beau Wadsworth
Sean Wallace
Steven Wallingford
Merrill Ward
Mark Wasserman
David Wedding Dress
Eric Weinstein
Jennifer Weiss
Marcus Wenzel
Peter Wilborn
Kurt Wiseman
Women’s Specialists of New Mexico, LTD.
Mark Wren
David Yale
Loretta Zainine
Christine Ziemer

Plus 1,926 individuals and 11 organizations that gave under $120. We appreciate you all.

If your name is not here and you would like it to be, or you have any questions or corrections, please let us know!

Contact: Aidan Boling, Operations Associate

Next Horizons Society

Join the Next Horizons Society and list your name as someone who has included MAPS in your planned gifts though a will, trust, retirement plan, life insurance policy and other options. Making a bequest is a simple, lasting way to help MAPS realize your vision, and carry that vision into the future.

To discuss your plans, please contact Jade at or call 831.429.6362.

Thank you to our Next Horizons Society members:

Peter Bynum
John Gilmore
Mark Hines
Lowell Sodeman II
Terry Turner

Fiscal Sponsorship Donors

This list includes donors who gave $120 or more to organizations that are fiscally sponsored by MAPS. Their support of this larger community is so greatly appreciated.

Ayahuasca Foundation

Grant Town $200,000



Paolo Deluca $1,400
Andreas Kimergård $500
Evey Marie Rogers $145


Cosmic Sister

Paul Ciarlo $244.20
Saroj Patel $773


Divinorum: The Documentary

Open Society $10,000
Anonymous $600


Ethnobotanical Stewardship Council (ESC)

Pippa Breakspear $120


From Shock to Awe

James Adjan $1,000
Steve Alpert $250
Soledad Archer $250
Robert J. Barnhart $5,000
Martin Birrittella $500
Sheila Burgel $200
Kimberly Cable $200
Edward G. Caccia $150
Andrea Campbell $350
Giancarlo Canavesio $500
Laura Cheney $150
Rachel Cohen $200
Jean Cote $200
Luc Cote $760
Caren D. Cross $500
Christian Douglas $500
Sandy Drooker $500
Steve Edelman $200
Macumba Films $500
Amy Freed $450
Gail E. Gibbons $500
Jill Gould $750
Nancy Leathers Graves $500
Monique Gregoire $250
Richard Grossman $500
Mac Gudgeon $200
Robbie Hart $500
Patricio Henriquez $500
Durga Katz $500
Teresa Keane $500
Marc Ketchel $500
Margaret Keys $300
Kenneth Koock $150
Kevin Kraus $5,000
Ninni Ladjevardi $150
Brian Lanes $264
Harmon Lisnow $500
Patrick Mathieu $153
Charles Mintz $250
Lorwen Nagle $300
Dennis Nelson $200
Eddie Oliver $500
Denis Parisien $200
Charles Phillips $200
Suzanne Pregerson $200
Erin Raskin $125
Diana & Richard Redmond $650
Diana Rogers $250
Adam Rosenberg $250
Nikolaus Rudy $200
James Sagert $185
Derik Sanders $200
Clare Strang $3,000
Richard Track $500
Andreas Vavaroutsos $250
Oliver J. Williams $250
Larry Wolinsky $200


Global Ibogaine Therapist Alliance (GITA)

Kenneth Alper $1,050
Harold Anderson $5,000
Tobias Erny $480
Martin Polanco Hesse $300
Chris & Dana Jenks $200
Barry Rossinoff $1,200


Huxley’s Exit

Anonymous   $6,000
Robert J. Barnhart $5,000
Siobhan Flanagan $200
Thomas Shanks $1,000
Kevin Sollows $350
Peter Van Der Heyden $2,500


International Center for Ethnobotanical Education, Research, and Service (ICEERS)

Danielle Barnett $300
Joëlle Castonguay $200
Richard Grossman $660
Debbie Mamic $150
David Michael $2,000
Soul Quest Inc. $400
Sita Sovin $1,397.10
Jason White $2,000
Diane Winter $1,000


ICEERS Ayahuasca Legal Defense Fund (ADF)

Jeffrey Bronfman $10,000
Steve Ellis $290
Moshe Tov Kreps $25,000


Sublime Visions

Seabrook Leaf $555
Richard Sundance Owen $125
Adriana Santiago $1,000
Dennis Totah $500


Wo/Men’s Alliance for Medical Marijuana (WAMM)

D. H. Gieringer & A. Agogoino $4,200